Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: A new light at the end of the tunnel
American Journal of Biopharmacy and Pharmaceutical Sciences · 2023
DOI: 10.25259/ajbps_14_2023 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Biopharmacy and Pharmaceutical Sciences, 2023. Verfasst von Chinonyelum Emmanuel Agbo und 4 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 24 Literaturangaben.
Abstract (Originalsprache)
Malaria, a perilous disease caused by Plasmodium parasites and characterized by a substantial mortality rate, has persistently posed as a global health challenge. Conventional antimalarial formulations, although effective, grapple with issues surrounding their bioavailability and palatability, and potentially hampering patient adherence and inadvertently fueling drug resistance and poor treatment outcomes. This paper meticulously delves into the predicaments associated with prevailing antimalarial delivery methods – oral, intravenous, and intramuscular. The paper navigates through the compelling merits of the transdermal pathway, drawing inspiration from its triumphant deployment in other medical realms. The investigation extends to encompass preclinical inquiries dedicated to exploring the transdermal administration of antimalarials. Transdermal antimalarials have shown complete suppression and elimination of Plasmodium parasites, as suggested by the preclinical studies. These preclinical studies emerge as a beacon of hope, exhibiting heightened bioavailability, enhanced safety margins, and notable cost-effectiveness when compared with oral antimalarials. Moreover, this innovative avenue for drug delivery not only offers convenience but also holds the potential to be a transformative solution to the adherence problems of traditional antimalarials, which currently afflicts standard therapeutic options.
Zitieren
APA
Agbo, C. E., Chima, U. E., Ogbobe, S. C., Omotayo, F. O., & David, S. C. (2023). Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: A new light at the end of the tunnel. American Journal of Biopharmacy and Pharmaceutical Sciences. https://doi.org/10.25259/ajbps_14_2023
Vancouver
Agbo CE, Chima UE, Ogbobe SC, Omotayo FO, David SC. Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: A new light at the end of the tunnel. American Journal of Biopharmacy and Pharmaceutical Sciences. 2023. doi:10.25259/ajbps_14_2023
BibTeX
@article{Agbo2023,
author = {Agbo, Chinonyelum Emmanuel and Chima, Uzochukwu Emmanuel and Ogbobe, Sunday Chibueze and Omotayo, Faith Olanrewaju and David, Success Chekwubechukwu},
title = {Transdermal antimalarial drug delivery to improve poor adherence to antimalarials: A new light at the end of the tunnel},
journal = {American Journal of Biopharmacy and Pharmaceutical Sciences},
year = {2023},
doi = {10.25259/ajbps_14_2023}
}
EUVIMED